Application of the CDAS-QoL scale in surgical decision-making for anorectal stricture in Crohn’s disease: a diagnostic accuracy study Authors: Jin-Rong Li, Shu-Hui Zhan, Xin-Yu Yang, Ying Sun, Chen-Chen Shan, Ning Ding, Wen-Jie Guo, Can Wang, Li-Chao Qiao, Yu Xiang, Yun-Fei Gu, Bo-Lin Yang, Yu-Xia Gong, Ping Zhu, Wei-Ming Zhu Published: 2026 ABSTRACT Anorectal stricture is a highly disabling complication of Crohn’s disease (CD). However, surgical decisions still rely largely on symptoms and anal canal calibre, with no standardised quantitative threshold. Using the psychometrically validated Crohn’s Disease Anorectal Stricture Quality of Life (CDAS-QoL) scale, we performed diagnostic accuracy analyses to link scores to multidisciplinary team (MDT)-defined surgical indication and derive a cut-off value for surgical risk stratification and shared decision-making. We conducted a single-centre diagnostic accuracy study in a retrospectively assembled cohort of patients with CD-associated anorectal stricture from January 2016 to November 2025. CDAS-QoL was prespecified as the index test, and MDT-defined surgical indication—based on symptoms, anal canal calibre, and imaging—served as the reference standard. A CDAS-QoL surgery-alert threshold was derived using receiver operating characteristic (ROC) analysis (Youden index) and a sensitivity-prioritised rule, and evaluated by bootstrap internal validation (1,000 resamples), stratified 5-fold cross-validation, and decision-curve analysis. Among 221 patients with CD-associated anorectal stricture, 57 (25.8%) underwent surgery after completing the CDAS-QoL. Baseline scores were higher in those who proceeded to surgery than in conservatively managed patients (85.3 ± 5.9 vs. 63.4 ± 15.2, p < 0.001). CDAS-QoL showed strong discrimination for MDT-defined surgical indication (AUC 0.89; 95% CI 0.85–0.93). A cut-off of 78.5 yielded 93% sensitivity and 81% specificity, classifying 84/221 (38.0%) as high risk. Internal validation (bootstrap and stratified 5-fold cross-validation) supported robustness, and decision-curve analysis suggested potential clinical utility. A threshold based on CDAS-QoL may identify patients with CD-associated anorectal stricture who have substantial functional impairment and should be prioritised for timely surgical evaluation, thereby facilitating shared decision-making. Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-63447-6. Introduction Anorectal stricture is a debilitating complication of Crohn’s disease (CD), affecting approximately 17%–22% of patients with perianal involvement1. While surgery is indicated for moderate-to-severe strictures refractory to medical therapy, clinical decision-making remains challenging due to the absence of a standardised assessment protocol2. Definitions of surgical indications vary widely, and the existing literature is further limited by small sample sizes and limited-quality evidence, resulting in a lack of objective, quantitative guidance. Current strategies for determining whether patients with CD-associated anorectal stricture require surgery rely mainly on symptom assessment, anal canal calibre, and structural findings on examination or imaging, all of which have certain limitations3–6. Patients may report only subtle symptomatic changes, such as narrower stools or incomplete evacuation, which can delay necessary intervention5,7. However, the same degree of narrowed anal canal calibre (for example 12 mm) may be associated with markedly different symptom burdens or disability across individuals. Thus, indications for surgical intervention remain insufficiently standardised and may vary according to clinician experience and local practice. Establishing clinically meaningful thresholds on quality of life (QoL) scales has emerged as a method to link patient-reported outcomes (PROs) with disease status and treatment needs8. One example is the “red warning zone” derived from the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which suggests that PRO-based thresholds may help inform surgical decision-making9. We developed the Crohn’s Disease Anorectal Stricture Quality of Life (CDAS-QoL) scale, a validated PROM to quantify the multidimensional impact of anorectal stricture. Unlike anatomical or clinician-assessed indicators alone, CDAS-QoL captures the patient’s experience of stricture-related symptoms, functional impairment, treatment burden, sexual concerns, worries, and psychosocial discomfort. The scale exhibits strong psychometric properties, including strong internal consistency, split-half reliability, test-retest reliability, and discriminability10. However, the diagnostic accuracy of CDAS-QoL scores for MDT-defined surgical indication remains unknown, limiting its clinical application. Therefore, this study uses a diagnostic accuracy approach to establish and validate a surgery-alert threshold based on CDAS-QoL scores. This threshold is intended to support risk stratification and inform timely surgical evaluation in CD-associated anorectal stricture. Methods Patients This was a diagnostic accuracy study of a cohort with CD-associated anorectal stricture. Patients were identified from the centre’s database of individuals with CD anorectal stricture at the Affiliated Hospital of Nanjing University of Chinese Medicine between January 2016 and November 2025. From July 2024 to November 2025, demographic characteristics, clinical history, and CDAS-QoL data were collected. The index date was defined as the date of questionnaire completion, and only surgical interventions occurring after the index date were analysed. The study flowchart is presented in Fig. 1. This study was reviewed and approved by the Institutional Review Board of the Affiliated Hospital of Nanjing University of Chinese Medicine. The requirement for informed consent was waived by the same Institutional Review Board because of the retrospective nature of the study. Fig. 1Study inclusion flowchart. n represents the number of patients. Study inclusion flowchart. n represents the number of patients. Eligibility criteria Inclusion criteria were as follows: (1) diagnosis of CD based on accepted clinical, endoscopic, radiologic, and histologic criteria; (2) anorectal stricture confirmed by digital rectal examination (DRE) and magnetic resonance imaging (MRI); and (3) age ≥ 14 years and able to complete the questionnaire independently. Exclusion criteria were as follows: (1) stricture from a non-CD cause; (2) existing stoma or faecal diversion; (3) absolute surgical contraindications (e.g., active sepsis); and (4) communication or cognitive impairments preventing reliable survey completion. CDAS-QoL scale The CDAS-QoL scale is a 21-item PROM comprising four domains. Items are scored on a 5-point Likert scale, yielding a total score from 21 to 105. Higher scores indicate worse quality of life and greater stricture-related functional burden10. Reference standard and surgical indication The reference standard was the presence of an MDT-defined surgical indication at the index assessment. Surgical indication was adjudicated by a colorectal surgeon–led MDT according to prespecified criteria. Surgery was indicated when at least two of the following were present: (i) definite stricture-related symptoms (e.g., difficulty with defecation or faecal incontinence); (ii) MRI evidence of anorectal stricture (with or without proximal dilatation); and (iii) markedly reduced anal canal patency on DRE (inability to pass an index finger, or a circumferential stricture ring causing evident luminal narrowing). Patients meeting ≤ 1 criterion were classified as not having a surgical indication. CDAS-QoL scores were not disclosed during MDT discussion. Threshold determination and statistical analysis Primary analysis The surgery-alert threshold was specified as the CDAS-QoL score that indicated a need for formal surgical evaluation. A receiver operating characteristic (ROC) curve was constructed to assess the ability of the CDAS-QoL score to discriminate according to the reference standard. The area under the curve (AUC) and its 95% confidence interval (CI) were estimated using DeLong’s method. An initial optimal cut-off was identified by maximising the Youden index. Subsequently, a sensitivity-prioritised rule (sensitivity ≥ 0.85) was applied, and from the eligible cut-offs, the score yielding the highest specificity was selected as the surgery-alert threshold. Internal validation and clinical utility Bootstrap internal validation with 1,000 resamples was performed to obtain optimism-corrected estimates of the AUC and classification metrics at the chosen threshold. Clinical utility was quantified using decision-curve analysis across a prespecified range of threshold probabilities11. Sensitivity analysis Stratified 5-fold cross-validation was conducted at the patient level to assess the robustness of model performance. During each iteration, the optimal probability cut-off was determined in the training fold using two prespecified rules (Youden index and sensitivity-prioritised), and then applied to the held-out validation fold to compute performance metrics, including AUC, accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Final performance was reported as the mean and standard deviation of these metrics across the five folds. Calibration and decision-curve analyses were similarly performed within each validation fold to evaluate consistency. Sample size estimation The sample size was estimated using the ROC methodology described by Hanley and McNeil12. Assuming an expected AUC of 0.80, a null hypothesis AUC of 0.65, α = 0.05, and β = 0.20, the minimum required sample size was approximately 180 patients. The target sample size was increased to 220 to accommodate potential missing data and to ensure robustness for internal validation procedures. Results Patient characteristics A total of 221 patients with CD-associated anorectal stricture were included. Of these, 49 (22.2%) met all three criteria, 8 (3.6%) met two criteria, and 164 (74.2%) met one or fewer criteria. At the index assessment, 57 patients (25.8%) met the MDT-defined surgical indication, and all underwent stricture-related surgery within 3 months of completing the CDAS-QoL (Supplementary Table S1). Baseline clinical characteristics are summarised in Table 1. The duration of stricture was significantly shorter in the MDT-indicated group (23.0 months, interquartile range [IQR] 8.5–56.0) compared with the non-indicated group (50.0 months, IQR 25.0–80.0) (p < 0.001). Table 1Participant characteristics.VariableOverall (n = 221)MDT-indicated group (n = 57)Non-indicated group (n = 164) p Gender0.308Male119 (53.8%)34 (59.6%)85 (51.8%)Female102 (46.2%)23 (40.4%)79 (48.2%)Age (years)36.5 ± 10.136.2 ± 10.136.7 ± 10.10.786BMI (kg/m²)20.2 ± 3.320.2 ± 3.620.2 ± 3.10.966Smoking0.174Never smoked187 (84.6%)45 (78.9%)142 (86.6%)Former smoker24 (10.9%)7 (12.3%)17 (10.4%)Current smoker10 (4.5%)5 (8.8%)5 (3.0%)Duration of CD (months)95.8 ± 71.288.0 ± 61.798.5 ± 74.20.338Duration of stricture (months)45.0 (18.3, 75.8)23.0 (8.5, 56.0)50.0 (25.0, 80.0)< 0.001Montreal classification at CD diagnosisAge0.806A1 ≤ 1620 (9.0%)6 (10.5%)14 (8.5%)A2 17–40165 (74.7%)43 (75.4%)122 (74.4%)A3 > 4036 (16.3%)8 (14.0%)28 (17.1%)Location0.744L1-ileal24 (10.9%)6 (10.5%)18 (11.0%)L2-colonic80 (36.2%)18 (31.6%)62 (37.8%)L3-ileo-colonic117 (52.9%)33 (57.9%)84 (51.2%)Behavior0.315B1-nonpenetrating nonstricturing20 (9.0%)6 (10.5%)14 (8.5%)B2-stricturing167 (75.6%)39 (68.4%)128 (78.0%)B3-penetrating34 (15.4%)12 (21.1%)22 (13.4%)Type of stricture operations-Transanal stricturotomy27 (12.2%)27 (47.4%)–Transanal stricturectomy28 (12.7%)28 (49.1%)–Rectal resection2 (0.9%)2 (3.5%)–Medical treatment5-ASA11 (5.0%)1 (1.8%)10 (6.1%)0.344Anti-TNF agent37 (16.7%)6 (10.5%)31 (18.9%)0.145IL-12/23 antagonist142 (64.3%)39 (68.4%)103 (62.8%)0.446Anti-integrin3 (1.4%)2 (3.5%)1 (0.6%)0.335JAK1 inhibitor13 (5.9%)6 (10.5%)7 (4.3%)0.084Immunosuppressant11 (5.0%)011 (6.7%)0.098Enteral nutrition4 (1.8%)3 (5.3%)1 (0.6%)0.090Data are presented as mean ± SD, median (IQR), or n (%). CD Crohn’s disease, BMI body mass index; 5-ASA, 5-aminosalicylic acid; TNF tumour necrosis factor, IL interleukin, JAK Janus kinase. Table 1Participant characteristics.VariableOverall (n = 221)MDT-indicated group (n = 57)Non-indicated group (n = 164) p Gender0.308Male119 (53.8%)34 (59.6%)85 (51.8%)Female102 (46.2%)23 (40.4%)79 (48.2%)Age (years)36.5 ± 10.136.2 ± 10.136.7 ± 10.10.786BMI (kg/m²)20.2 ± 3.320.2 ± 3.620.2 ± 3.10.966Smoking0.174Never smoked187 (84.6%)45 (78.9%)142 (86.6%)Former smoker24 (10.9%)7 (12.3%)17 (10.4%)Current smoker10 (4.5%)5 (8.8%)5 (3.0%)Duration of CD (months)95.8 ± 71.288.0 ± 61.798.5 ± 74.20.338Duration of stricture (months)45.0 (18.3, 75.8)23.0 (8.5, 56.0)50.0 (25.0, 80.0)< 0.001Montreal classification at CD diagnosisAge0.806A1 ≤ 1620 (9.0%)6 (10.5%)14 (8.5%)A2 17–40165 (74.7%)43 (75.4%)122 (74.4%)A3 > 4036 (16.3%)8 (14.0%)28 (17.1%)Location0.744L1-ileal24 (10.9%)6 (10.5%)18 (11.0%)L2-colonic80 (36.2%)18 (31.6%)62 (37.8%)L3-ileo-colonic117 (52.9%)33 (57.9%)84 (51.2%)Behavior0.315B1-nonpenetrating nonstricturing20 (9.0%)6 (10.5%)14 (8.5%)B2-stricturing167 (75.6%)39 (68.4%)128 (78.0%)B3-penetrating34 (15.4%)12 (21.1%)22 (13.4%)Type of stricture operations-Transanal stricturotomy27 (12.2%)27 (47.4%)–Transanal stricturectomy28 (12.7%)28 (49.1%)–Rectal resection2 (0.9%)2 (3.5%)–Medical treatment5-ASA11 (5.0%)1 (1.8%)10 (6.1%)0.344Anti-TNF agent37 (16.7%)6 (10.5%)31 (18.9%)0.145IL-12/23 antagonist142 (64.3%)39 (68.4%)103 (62.8%)0.446Anti-integrin3 (1.4%)2 (3.5%)1 (0.6%)0.335JAK1 inhibitor13 (5.9%)6 (10.5%)7 (4.3%)0.084Immunosuppressant11 (5.0%)011 (6.7%)0.098Enteral nutrition4 (1.8%)3 (5.3%)1 (0.6%)0.090Data are presented as mean ± SD, median (IQR), or n (%). CD Crohn’s disease, BMI body mass index; 5-ASA, 5-aminosalicylic acid; TNF tumour necrosis factor, IL interleukin, JAK Janus kinase. Participant characteristics. Data are presented as mean ± SD, median (IQR), or n (%). CD Crohn’s disease, BMI body mass index; 5-ASA, 5-aminosalicylic acid; TNF tumour necrosis factor, IL interleukin, JAK Janus kinase. Quality of life in CD-associated anorectal stricture The mean (standard deviation [SD]) total CDAS-QoL score in the overall cohort was 69.0 (16.5). Patients meeting the MDT-defined indication for surgery at the index assessment had significantly higher CDAS-QoL scores than those not meeting the MDT indication (85.3 ± 5.9 vs. 63.4 ± 15.2, p < 0.001; Fig. 2). This difference was consistent across all CDAS-QoL domains (Table 2), indicating broader impairment among patients deemed to meet MDT-defined surgical indications. Fig. 2CDAS-QoL scores by MDT-defined surgical indication with the surgery-alert threshold. Boxplot comparing CDAS-QoL scores between patients with and without MDT-defined surgical indication. The green dashed line represents the surgery-alert threshold at 78.5 points. CDAS-QoL scores by MDT-defined surgical indication with the surgery-alert threshold. Boxplot comparing CDAS-QoL scores between patients with and without MDT-defined surgical indication. The green dashed line represents the surgery-alert threshold at 78.5 points. Table 2Total and domain-specific CDAS-QoL scores according to MDT-defined surgical indication.VariableOverall (n = 221)MDT-indicated group (n = 57)Non-indicated group (n = 164) p Total CDAS-QoL score69.0 ± 16.585.3 ± 5.963.4 ± 15.2< 0.001Symptom experience21.1 ± 7.429.1 ± 3.118.3 ± 6.4< 0.001Treatment burden and sexual concerns9.8 ± 2.811.7 ± 1.89.1 ± 2.7< 0.001Worries and concerns23.8 ± 6.028.1 ± 3.122.3 ± 6.0< 0.001Psychosocial discomfort14.4 ± 3.416.3 ± 2.013.8 ± 3.5< 0.001Data are presented as mean ± SD. CD Crohn’s disease, CDAS-QoL Crohn’s Disease Anorectal Stricture Quality of Life scale. Table 2Total and domain-specific CDAS-QoL scores according to MDT-defined surgical indication.VariableOverall (n = 221)MDT-indicated group (n = 57)Non-indicated group (n = 164) p Total CDAS-QoL score69.0 ± 16.585.3 ± 5.963.4 ± 15.2< 0.001Symptom experience21.1 ± 7.429.1 ± 3.118.3 ± 6.4< 0.001Treatment burden and sexual concerns9.8 ± 2.811.7 ± 1.89.1 ± 2.7< 0.001Worries and concerns23.8 ± 6.028.1 ± 3.122.3 ± 6.0< 0.001Psychosocial discomfort14.4 ± 3.416.3 ± 2.013.8 ± 3.5< 0.001Data are presented as mean ± SD. CD Crohn’s disease, CDAS-QoL Crohn’s Disease Anorectal Stricture Quality of Life scale. Total and domain-specific CDAS-QoL scores according to MDT-defined surgical indication. Data are presented as mean ± SD. CD Crohn’s disease, CDAS-QoL Crohn’s Disease Anorectal Stricture Quality of Life scale. CDAS-QoL discrimination and threshold derivation CDAS-QoL showed strong discrimination between patients with and without an MDT-defined indication for surgery at the index assessment (AUC 0.89; standard error [SE] 0.02; 95% CI 0.85–0.93; p < 0.001). The maximum Youden index was 0.781, corresponding to a cut-off of 77.5 (sensitivity 0.982; specificity 0.799). Using the prespecified sensitivity-prioritised criterion (sensitivity ≥ 0.85), the cut-off with the highest specificity was 78.5 (Fig. 3). At this surgery-alert threshold (CDAS-QoL ≥ 78.5), 63.1% of patients met the MDT-defined indication for surgery (and subsequently underwent surgery within 3 months), compared with 2.9% of those with CDAS-QoL < 78.5. Sensitivity and specificity at the 78.5 cut-off were 0.93 and 0.81, respectively (Table 3). Fig. 3Receiver operating characteristic (ROC) curve for identifying MDT-defined surgical indication using CDAS-QoL. The red dot indicates the cut-off score of 78.5. Receiver operating characteristic (ROC) curve for identifying MDT-defined surgical indication using CDAS-QoL. The red dot indicates the cut-off score of 78.5. Table 3Performance of the CDAS-QoL surgery-alert threshold (≥ 78.5 points).CDAS-QoL categoryn (%)MDT-defined indication for surgery, n(%)SensitivitySpecificityLR⁺LR⁻≥ 78.5 (high risk)84 (38.0%)53 (63.1%)0.930.814.920.09< 78.5 (low risk)137 (62.0%)4 (2.9%)Data are presented as n (%). Percentages in the MDT-defined indication column are calculated within each CDAS-QoL category. Sensitivity, specificity, LR⁺ and LR⁻ were calculated for the cut-off CDAS-QoL ≥ 78.5, with test-positive defined as CDAS-QoL ≥ 78.5.CDAS-QoL Crohn’s Disease Anorectal Stricture Quality of Life scale, MDT multidisciplinary team, LR⁺ positive likelihood ratio, LR⁻ negative likelihood ratio. Table 3Performance of the CDAS-QoL surgery-alert threshold (≥ 78.5 points).CDAS-QoL categoryn (%)MDT-defined indication for surgery, n(%)SensitivitySpecificityLR⁺LR⁻≥ 78.5 (high risk)84 (38.0%)53 (63.1%)0.930.814.920.09< 78.5 (low risk)137 (62.0%)4 (2.9%)Data are presented as n (%). Percentages in the MDT-defined indication column are calculated within each CDAS-QoL category. Sensitivity, specificity, LR⁺ and LR⁻ were calculated for the cut-off CDAS-QoL ≥ 78.5, with test-positive defined as CDAS-QoL ≥ 78.5.CDAS-QoL Crohn’s Disease Anorectal Stricture Quality of Life scale, MDT multidisciplinary team, LR⁺ positive likelihood ratio, LR⁻ negative likelihood ratio. Performance of the CDAS-QoL surgery-alert threshold (≥ 78.5 points). Data are presented as n (%). Percentages in the MDT-defined indication column are calculated within each CDAS-QoL category. Sensitivity, specificity, LR⁺ and LR⁻ were calculated for the cut-off CDAS-QoL ≥ 78.5, with test-positive defined as CDAS-QoL ≥ 78.5. CDAS-QoL Crohn’s Disease Anorectal Stricture Quality of Life scale, MDT multidisciplinary team, LR⁺ positive likelihood ratio, LR⁻ negative likelihood ratio. Bootstrap internal validation Bootstrap internal validation (B = 1,000), repeating the full threshold-selection procedure in each resample (sensitivity ≥ 0.85 with maximal specificity), indicated minimal optimism. For the final surgery-alert threshold of 78.5, the optimism-corrected sensitivity was 0.93, closely aligning with the apparent estimate, and the bootstrap distribution of sensitivity was consistently clustered around this value (Fig. 4). The corresponding optimism-corrected specificity and accuracy were 0.81 and 0.84 (Supplementary Table S2 and Supplementary Figure S1). Decision-curve analysis showed that the CDAS-QoL threshold strategy provided greater net benefit than the treat-all and treat-none strategies across the prespecified clinically relevant threshold probability range of 3%–25% (Fig. 5). Fig. 4Bootstrap distribution of sensitivity at the CDAS-QoL surgery-alert threshold of 78.5 points. The histogram shows the distribution of bootstrap-estimated sensitivity across 1,000 resamples. The red dashed line indicates the mean sensitivity, and the yellow dashed lines indicate the 95% confidence interval. The mean bootstrap-estimated sensitivity was 0.93, with a 95% confidence interval of 0.85–0.98. Bootstrap distribution of sensitivity at the CDAS-QoL surgery-alert threshold of 78.5 points. The histogram shows the distribution of bootstrap-estimated sensitivity across 1,000 resamples. The red dashed line indicates the mean sensitivity, and the yellow dashed lines indicate the 95% confidence interval. The mean bootstrap-estimated sensitivity was 0.93, with a 95% confidence interval of 0.85–0.98. Fig. 5Decision-curve analysis of the CDAS-QoL for surgical indication in CD-associated anorectal stricture. Net benefit is plotted against threshold probability. The blue curve represents the threshold strategy using CDAS-QoL ≥78.5, while the red and green curves represent the treat-all and treat-none strategies, respectively. A higher net benefit indicates greater clinical utility. Decision-curve analysis of the CDAS-QoL for surgical indication in CD-associated anorectal stricture. Net benefit is plotted against threshold probability. The blue curve represents the threshold strategy using CDAS-QoL ≥78.5, while the red and green curves represent the treat-all and treat-none strategies, respectively. A higher net benefit indicates greater clinical utility. Cross-validation In stratified 5-fold cross-validation, performance remained stable across validation folds. Discrimination was maintained (mean AUC 0.885 ± 0.049) with an accuracy of 0.842 ± 0.035. Classification metrics were sensitivity 0.931 ± 0.044, specificity 0.813 ± 0.039, PPV 0.619 ± 0.143, and NPV 0.970 ± 0.017 (Fig. 6). Fig. 6Cross-validation performance across validation folds. Boxplot showing the cross-validation performance for key metrics of the CDAS-QoL, including accuracy, area under the curve (AUC), negative predictive value (NPV), positive predictive value (PPV), sensitivity and specificity. AUC represents the area under the ROC curve, while NPV and PPV reflect the predictive values of the threshold strategy. Sensitivity and specificity indicate the ability to correctly identify positive and negative cases, respectively. Cross-validation performance across validation folds. Boxplot showing the cross-validation performance for key metrics of the CDAS-QoL, including accuracy, area under the curve (AUC), negative predictive value (NPV), positive predictive value (PPV), sensitivity and specificity. AUC represents the area under the ROC curve, while NPV and PPV reflect the predictive values of the threshold strategy. Sensitivity and specificity indicate the ability to correctly identify positive and negative cases, respectively. Discussion In this study, we established a CDAS-QoL-based surgery-alert threshold to identify patients with CD-associated anorectal stricture who may require surgical intervention. Using an MDT-defined surgical indication as the reference standard, a cut-off score of 78.5 identified patients with significantly greater functional burden and demonstrated consistently strong discriminatory performance, as confirmed by internal validation and cross-validation (AUC 0.885). This threshold provides a straightforward, patient-centred indicator for prioritising surgical assessment. Two candidate thresholds were evaluated, reflecting different clinical trade-offs. The Youden cut-off (77.5) maximised overall classification accuracy, achieving very high sensitivity (0.982) but moderate specificity (0.799). A prespecified sensitivity-prioritised strategy selected a threshold of 78.5 to better identify patients with an MDT-defined surgical indication by improving specificity (0.81) while maintaining high sensitivity (0.93). Given the aim of supporting clinical triage without generating excessive false-positive referrals for formal surgical evaluation, 78.5 was selected as the preferred surgery-alert threshold. The CDAS-QoL instrument provides complementary information not fully captured by conventional clinical assessments. The strong association between higher CDAS-QoL scores and MDT-defined surgical indications underscores that the scale reflects the consequential day-to-day functional and psychological burden of anorectal stricture. In preoperative evaluation, CDAS-QoL can facilitate shared decision-making. Evidence from other fields, such as knee arthroplasty, demonstrates that integrating PROMs enhances patient satisfaction and engagement13. In CD, a generic “red-yellow-green” framework based on the SIBDQ has shown acceptable performance in distinguishing surgically relevant quality-of-life thresholds9. In the present study, the phenotype-specific design of CDAS-QoL for anorectal stricture may partly explain its observed discriminatory performance for MDT-defined surgical indication. These findings support further evaluation of condition-specific PROMs when surgical decisions are primarily guided by functional burden. This study advances prior approaches by positioning CDAS-QoL not as a secondary outcome measure but as a primary decision-support tool that standardises patient-reported impairment into a trigger for surgical review. It is not intended to replace physical examination or imaging, but to complement them by refocusing clinical attention from anatomical narrowing alone to integrated functional impact at the point of care. Methodological strengths of this study include a prespecified composite reference standard adjudicated by a blinded multidisciplinary team, consecutive patient enrolment, and adherence to Standards for Reporting Diagnostic Accuracy Studies (STARD) 2015 guidelines14. The robustness of the findings is reinforced by bootstrap validation, cross-validation, and decision-curve analysis. Furthermore, this work constitutes the largest reported cohort of patients with Crohn’s disease–associated anorectal stricture. Study limitations include the single-centre tertiary referral setting and lack of external validation. As the 78.5 threshold was derived and internally validated within the same cohort, its generalisability to centres with different patient populations, MDT structures, or surgical practices remains uncertain. Because this study was conducted in a tertiary referral inflammatory bowel disease and colorectal surgery centre, the cohort may also have been enriched for patients with more severe or complex anorectal strictures. In addition, the reference standard was a composite MDT-defined surgical indication. Although prespecified and clinically defensible for a decision-support study, this standard is not an independent objective gold standard and remains partly subjective and potentially centre-specific. Potential incorporation bias or construct overlap may also exist because symptom burden and functional impairment contributed to the MDT reference standard and are also captured by CDAS-QoL, although MDT members were blinded to CDAS-QoL scores. Although there was a significant difference in stricture duration between groups, stricture duration was not used as a deciding factor in MDT surgical decision-making. Future multicentre external validation is needed to confirm the reproducibility, generalisability, and clinical utility of the proposed threshold. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4